Evolution of a chemosensitive core-binding factor AML into an aggressive leukemia with eosinophilic differentiation

Blood Adv. 2018 Jul 10;2(13):1517-1521. doi: 10.1182/bloodadvances.2018016675.

Abstract

  1. Core-binding factor AML can evolve from good-risk disease into aggressive disease through the gain of additional genomic aberrations.

  2. In this unique case, an AML patient died of hypereosinophilic syndrome with solid organ infiltration of differentiated eosinophils.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Clonal Evolution*
  • Core Binding Factors*
  • Disease Progression
  • Eosinophils / pathology*
  • Fatal Outcome
  • Humans
  • Hypereosinophilic Syndrome / etiology
  • Leukemia, Myeloid, Acute / classification
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / pathology*
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Neoplasm Invasiveness
  • Oncogene Proteins, Fusion
  • Remission Induction / methods

Substances

  • Core Binding Factors
  • Oncogene Proteins, Fusion
  • inv(16) fusion protein, human